FY2025 · period end Dec '25 · from the 10-K filed Mar 24, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | negative: -$0.05B | negative: -$0.04B | negative: -$0.03B | negative: -$0.04B | negative: -$0.03B |
| EPS (Diluted) | negative: -$1.25 | negative: -$1.24 | negative: -$1.50 | negative: -$4.00 | negative: -$4.08 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $0.04B | $0.04B | $0.02B | $0.03B | $0.05B |
| Total Liabilities | $0.02B | $0.02B | $0.02B | $0.02B | $0.02B |
| Stockholders' Equity | $0.02B | $0.02B | negative: -$0.00B | $0.01B | $0.03B |
| Cash & Equivalents | $0.02B | $0.01B | $0.02B | $0.02B | $0.04B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | negative: -$0.05B | negative: -$0.03B | negative: -$0.02B | negative: -$0.04B | negative: -$0.03B |
| Capital Expenditures | $0.00B | — | $0.00B | — | — |
| Free Cash Flow | negative: -$0.05B | — | negative: -$0.02B | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | — | — | — | — | — |
| Net Margin | — | — | — | — | — |
| Return on Equity | negative: -257.7% | negative: -190.6% | 2059.0% | negative: -233.0% | negative: -101.5% |
| Return on Assets | negative: -135.9% | negative: -137.3% | negative: -120.9% | negative: -109.3% | negative: -75.5% |
| Debt / Equity | — | — | — | — | — |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0001193125-26-344571 | Aug 11, 2026 | Aug 11, 2026 | Aug 11, 2026 20:04 UTC | EDGAR |
| 10-Q | 0001193125-26-344624 | Jun 30, 2026 | Aug 11, 2026 | Aug 11, 2026 20:09 UTC | EDGAR |
| 8-K | 0001193125-26-296174 | Jul 2, 2026 | Jul 6, 2026 | Jul 6, 2026 20:06 UTC | EDGAR |
| 8-K | 0001193125-26-252624 | May 29, 2026 | Jun 2, 2026 | Jun 2, 2026 12:51 UTC | EDGAR |
| 8-K | 0001193125-26-218175 | May 7, 2026 | May 12, 2026 | May 12, 2026 11:20 UTC | EDGAR |
| 10-Q | 0001193125-26-218177 | Mar 31, 2026 | May 12, 2026 | May 12, 2026 11:21 UTC | EDGAR |
| 10-K/Aamend | 0001193125-26-197402 | Dec 31, 2025 | Apr 30, 2026 | Apr 30, 2026 20:20 UTC | EDGAR |
| 8-K | 0001193125-26-159189 | Apr 15, 2026 | Apr 16, 2026 | Apr 16, 2026 20:47 UTC | EDGAR |
Direct links to SEC EDGAR. ACHV has additional filings available on the SEC site.
6 numbers ACHIEVE LIFE SCIENCES, INC. later changed — same XBRL tag, both filings linked.
Stockholders' Equity Attributable to Parent·As of Dec 31, 2016
Major restatementwas$19M
Revised down in a 10-K.
Net Income (Loss) Attributable to Parent·Q2 2016
Major restatementwas-$6.9M
Revised up in a 10-K.
Stockholders' Equity Attributable to Parent·As of Dec 31, 2015
Major restatementwas$37.4M
Revised down in a 10-K.
Net Income (Loss) Attributable to Parent·Q2 2017
Major restatementwas-$3M
Revised up in a 10-K.
Net Income (Loss) Attributable to Parent·Q1 2017
Major restatementwas-$3.3M
Revised up in a 10-K.
Net Income (Loss) Attributable to Parent·Q1 2016
Major restatementwas-$3.7M
Revised up in a 10-K.
ACHV is not the only one.
See every restatement we've found across the market — or get an alert the next time ACHV revises a number.
Restatements are detected by comparing every vintage of a fact across all of ACHIEVE LIFE SCIENCES, INC.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows ACHV's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling ACHIEVE LIFE SCIENCES, INC. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on ACHV yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on ACHV and publish the result to your public profile.
Ask about ACHIEVE LIFE SCIENCES, INC.
Continue in Workspace — cited answers on ACHV, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs